Preparation Procedure of compound derived from polymorphic pyrazolo [3,4-d] pyrimidine； Salt of the compound, Pharmaceutical composition containing same and Use thereof in the treatment of a disorder associated with mTOR.
Polymorphs, hydrates, and solvates of chemical compounds that modulate kinase activity, including mTOR activity, and chemical compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mTOR activity, are described herein.Forma cristalina A de un compuesto de fórmula I, composición farmacéutica que comprende al compuesto de fórmula I, uso de la composición en la preparación de un medicamento útil para el tratamiento de un trastorno asociado a mTOR, y procedimiento de preparación de la Forma cristalina A.
